Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European stocks log steepest one-day fall this year as banks extend slide

Mon, 13th Mar 2023 17:13

European banks log worst two-day selloff in a year

*

Credit Suisse tumbles to fresh record low

*

HSBC rescues Silicon Valley Bank's UK arm

*

Energy firms dip on lower oil prices

March 13 (Reuters) - European stocks logged their steepest one-day fall this year on Monday on continued drag from banking stocks even as authorities stepped in to limit the fallout from the sudden collapse of Silicon Valley Bank.

The pan-European STOXX 600 index closed the day 2.3% lower, with bank, financials and insurer stocks, along with energy stocks, bearing the brunt of selling pressure.

European banking stocks dropped 5.7%, notching their worst two-day selloff since the Russia-Ukraine war broke out early last year.

Worries around the resilience of the sector's balance sheet in the face of SVB's collapse have rattled investors.

"Investors have been shaken by the events of the past few days, and are waiting with bated breath to see if repercussions in the financial sector will spill over and create pools of fresh problems," said Susannah Streeter, head of money and markets at Hargreaves Lansdown.

The wider risk-off moves sent Credit Suisse shares down 9.6% to a fresh record low.

Germany's Commerzbank slumped 12.7%, France's Societe Generale and Spain's Sabadell fell 6.2% and 11.4%, respectively.

HSBC dropped 4.1% after the British bank acquired the UK subsidiary of SVB for 1 pound, rescuing a key lender for technology start-ups in Britain.

However, euro zone banking supervisors saw limited consequences for the region's banks from the collapse of the U.S. lenders, while Moody's Investors Service noted that Europe's banks were unlikely to get hit by bond portfolio losses.

In addition, Morgan Stanley analysts noted that strong liquidity in European banks' balance sheet structure should avoid any forced unwinding or selling of bond portfolios.

The Federal Reserve and U.S. Treasury have announced a range of measures to stabilise the banking system and said SVB depositors would have access to their deposits on Monday.

Meanwhile, the stress in the financial sector has sparked expectations of a slowdown in the Fed's aggressive monetary tightening, with investors seeing a 68% chance of a 25 basis points (bps) hike next week, a drastic change from the 50-bps hike priced in previously.

Goldman Sachs no longer expects a rate hike from the Fed.

On the other hand, the ECB looks set to hike rates by 50 bps later this week.

Among others, Shell, BP and TotalEnergies SE lost between 4% and 5% tracking lower oil prices.

France's Sanofi SA dropped 1.7% on plans to acquire Provention Bio Inc for $2.9 billion. (Reporting by Sruthi Shankar and Ankika Biswas in Bengaluru; Editing by Savio D'Souza, Uttaresh Venkateshwaran and Christina Fincher)

More News
13 Jun 2022 09:09

Sanofi says next-gen COVID booster shot has potential against main variants

PARIS, June 13 (Reuters) - French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

Read more
10 Jun 2022 09:33

GSK closer to cracking elusive vaccine for common respiratory virus

LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

Read more
30 May 2022 17:34

European shares rise as China growth hopes boost luxury, tech stocks

May 30 (Reuters) - European shares touched their highest level in almost a month on Monday, with optimism buoyed by China's easing of COVID-19 restrictions and adding of new stimulus.

Read more
25 May 2022 11:03

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

Read more
28 Apr 2022 16:17

Strong earnings spur rally across European stocks

April 28 (Reuters) - European shares moved further off six-week lows hit last session as forecast-beating results from companies including energy major TotalEnergies and automaker Volvo Car helped set aside worries about slowing global economic growth.

Read more
30 Mar 2022 09:01

What to own in uncertain times

WHAT TO OWN IN UNCERTAIN TIMES (0859 GMT)

Read more
17 Mar 2022 13:56

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.

Read more
17 Mar 2022 13:34

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.

Read more
14 Mar 2022 10:18

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.

Read more
14 Mar 2022 09:11

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Read more
23 Feb 2022 15:31

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 12:44

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 10:22

Healthcare companies Sanofi and GSK to seek COVID-19 vaccine regulatory approval

PARIS, Feb 23 (Reuters) - Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Read more
18 Feb 2022 09:00

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.